Citation: | XU Kun, REN Xiuyan, WU Dan, LI Ziying, LUO Feng, LIANG Shuang, YUAN Bo, FENG Zhe, ZENG Ziqiang, WANG Guobao, ZHAO Chunrui. Study on Key Process Parameter for Separation and Preparation of High Abundance Ytterbium 176 Isotopes by Electromagnetic Method[J]. Atomic Energy Science and Technology, 2023, 57(3): 666-672. DOI: 10.7538/yzk.2022.youxian.0309 |
[1] |
张锦明,杜进. 中国放射性药物制备的现状及展望[J]. 同位素,2019,24(3):178-185.
ZHANG Jinming, DU Jin. Preparation of radiopharmaceuticals in China: Current status and prospects[J]. Journal of Isotopes, 2019, 24(3): 178-185(in Chinese). |
[2] |
王正,徐建锋,蔡玉婷,等. 中国放射性药物的现状及发展趋势[J]. 中国食品药品监管,2018,25(7):44-49.
WANG Zheng, XU Jianfeng, CAI Yuting, et al. Current staus and development trend of radiopharmaceuticals in China[J]. China Food Drug Administration, 2018, 25(7): 44-49(in Chinese). |
[3] |
冯婷婷,成伟华,王斌,等. 177Lu标记放射性药物临床研究进展[J]. 标记免疫分析与临床,2018,25(11):180-186.
FENG Tingting, CHENG Weihua, WANG Bin, et al. The progress in clinical research of 177Lu labeled radiopharmaceuticals[J]. Labeled Immunoassays and Clinical Medicine, 2018, 25(11): 180-186(in Chinese). |
[4] |
MITTRA E S. Neuroendocrine tumor therapy: 177Lu-DOTATATE[J]. American Journal of Roentgenology, 2018, 211(2): 1-8.
|
[5] |
温健男,程超,陈锐,等. 177Lu-PSMA-617治疗转移性去势抵抗性前列腺癌新进展[J]. 第二军医大学学报,2021,42(4):377-384.
WEN Jiannan, CHENG Chao, CHEN Rui, et al. 177Lu-PSMA-617 in treatment of metastatic castration-resistant prostate cancer: An update[J]. Academic Journal of Second Military Medical University, 2021, 42(4): 377-384(in Chinese). |
[6] |
卜婷,张川,臧士明,等. 177Lu-PSMA-617治疗转移性前列腺癌的安全性和疗效[J]. 中华核医学与分子影像杂志,2019,39(2):81-85.
BU Ting, ZHANG Chuan, ZANG Shiming, et al. Safety and efficacy of 177Lu-PSMA-617 therapy in metastatic castrationresistant prostate cancer[J]. Chinese Journal of Nuclear Medicine and Molecular Imaging, 2019, 39(2): 81-85(in Chinese). |
[7] |
WATANABE S, HASHIMOTO K, WATANABE S, et al. Production of highly purified no-carrier-added Lu for radioimmunotherapy[J]. Journal of Radioanalytical and Nuclear Chemistry, 2015, 303(1): 935-940.
|
[8] |
彭述明,杨宇川,谢翔,等. 我国堆照医用同位素生产及应用现状与展望[J]. 科学通报,2020,65(32):3526-3537.
PENG Shuming, YANG Yuchuan, XIE Xiang, et al. Current status and prospects of reactor produced medical radioisotopes in China[J]. Chinese Science Bulletin, 2020, 65(32): 3526-3537(in Chinese). |
[9] |
CHRISTOPH B. Production of non-carrier added (n.c.a.) 177Lu for radiopharmaceutical applica-tions[D]. Heidelberg: Fakult-t für Chemie, 2011.
|
[10] |
TARASOV V A, ANDREEV O I, ROMANOV E G, et al. Production of no-carrier added lutetium-177 by irradiation of enriched ytterbium 176[J]. Current Radiopharmaceuticals, 2015, 8(2): 95-106.
|
[11] |
PARK H, KWON D, CHA Y. Stable isotope production of 168Yb and 176Yb for industrial and medical applications[J]. Journal of Nuclear Science and Technology, 2008(6): 111-116.
|
[12] |
徐昆,任秀艳,毋丹,等. 镱同位素电磁分离束流接收与监测系统研制[J]. 同位素,2021,34(3):189-194.
XU Kun, REN Xiuyan, WU Dan, et al. Development of beam receiving and monitoring system for ytterbium isotope electromagnetic separation[J]. Journal of Isotopes, 2021, 34(3): 189-194(in Chinese). |
[13] |
任秀艳,米亚静,曾自强,等. 62Ni同位素的分离制备[J]. 原子能科学技术,2014,48(11):2111-2115.
REN Xiuyan, MI Yajing, ZENG Ziqiang, et al. Separation and preparation of 62Ni isotope[J]. Atomic Energy Science and Technology, 2014, 48(11): 2111-2115(in Chinese). |
[14] |
肖啸菴. 同位素分离[M]. 北京:原子能出版社,1999.
|
[15] |
BRUNETTI B, PIACENTE V, SCARDALA P. Vaporization study of YbCl3, YbBr3, YbI2, LuCl3, LuBr3, and LuI3 and a new assessment of sublimation enthalpies of rare earth trichlorides[J]. Journal of Chemical and Engineering Data, 2005, 50(6): 1801-1813.
|